The Breast Program - Translational Cancer Resource

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02798341

Acronym

TRACR

Enrollment

4000

Registered

2016-06-14

Start date

2012-07-01

Completion date

2030-07-01

Last updated

2026-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

TRACR will provide a data/biospecimen repository for translational research to better diagnose, prognose, treat and cure breast cancer (and related diseases/treatment conditions). Patients at the Rowan Breast Center will be consented for donation of blood and if available tumor/healthy/archived tissue. Patients will be consented to give permission to use said specimens for future research and to be contacted in the future about other research participation and additional information.

Interventions

OTHERBiospecimen Collection

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* RBC patients with known invasive cancer pre-surgery (greater or equal to 1.5cm) are given priority in recruitment. * RBC patients with known invasive cancer pre-surgery (less then 1.5cm). 3. RBC patients who are postsurgery for invasive breast cancer (performed at UPHS or non-UPHS entities). * Patients that are of high risk for breast cancer (family history, known deleterious genetic mutation(s)) seeking a prophylactic mastectomy at the breast clinic. * Only persons who can understand and give informed consent will be eligible to participate in this study. Furthermore, no persons belonging to vulnerable populations with as children (below 18 years of age), fetuses, neonates or prisoners will be recruited in this study. Pregnant women, who are pre-surgery and having surgery for clinical reasons, can still be recruited for tissue and blood collection.

Exclusion criteria

* Individual who cannot understand and give informed consent (cognitively impaired persons) * Children (below 18 years of age), fetuses and neonates * Prisoners

Design outcomes

Primary

Measure	Time frame
Number of biospecimen collected	15 years

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORAngela DeMichele, MD

Abramson Cancer Center at Penn Medicine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 6, 2026